Ustekinumab biosimilar (Samsung Bioepis)

乌司奴单抗生物类似药（Samsung Bioepis）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameUstekinumab biosimilar (Samsung Bioepis)
Drug Alias NameUstekinumab-ttwePyzchivaEksunbiSB-17SB17
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 subunit beta inhibitorsInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12 subunit betaInterleukin-12Interleukin-23
Therapy Area/IndicationsPlaque psoriasisInflammationPsoriasis +[9] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2024/04/19
Country/TerritoryCzechiaUnited StatesUkraine +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNipro CorpSandoz IncSamsung Bioepis Nl Bv +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisInflammationPsoriasis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG